Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2021
Top Holdings41 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
HORIZON THERAPEUTICS PLC | 9.3M | $1B | 17.0% | — | — | 11 qtrssince 2019-Q2 | Increased 65 |
MIRATI THERAPEUTICS INC | 5.1M | $744.5M | 12.7% | — | — | 12 qtrssince 2019-Q1 | Increased 63 |
UNITED THERAPEUTICS CORP | 3M | $655.8M | 11.2% | $150.28 | +43.19% | 5 qtrssince 2020-Q4 | Increased 63 |
APELLIS PHARMACEUTICALS INC | 8.6M | $404.5M | 6.9% | $40.72 | +17.74% | 4 qtrssince 2021-Q1 | Increased 91 |
ARGENX SE - ADR | 965,000 | $337.9M | 5.8% | $143.32 | +144.35% | 12 qtrssince 2019-Q1 | Increased 62 |
AVI BIOPHARMA INC | 3.1M | $281.4M | 4.8% | $104.50 | -13.31% | 12 qtrssince 2019-Q1 | Increased 70 |
ASCENDIS PHARMA A/S | 2M | $269.1M | 4.6% | $135.20 | +0.89% | 3 qtrssince 2021-Q2 | Increased 58 |
BIOMARIN PHARMACEUTICAL INC | 2.8M | $247.4M | 4.2% | $85.58 | +4.09% | 12 qtrssince 2019-Q1 | Increased 79 |
AMICUS THERAPEUTICS INC | 18.5M | $213.7M | 3.6% | $11.32 | +3.08% | 12 qtrssince 2019-Q1 | Increased 60 |
ALNYLAM PHARMACEUTICALS INC | 1.1M | $182.3M | 3.1% | $166.95 | +2.44% | 3 qtrssince 2021-Q2 | Increased 70 |
IOVANCE BIOTHERAPEUTICS INC | 8.7M | $165.6M | 2.8% | $15.16 | +28.14% | 12 qtrssince 2019-Q1 | Increased 54 |
XENON PHARMACEUTICALS INC | 5M | $155.7M | 2.7% | $17.33 | +84.63% | 12 qtrssince 2019-Q1 | Increased 69 |
IVERIC BIO INC | 7.3M | $121.2M | 2.1% | — | — | 7 qtrssince 2020-Q2 | Increased 54 |
MADRIGAL PHARMACEUTICALS INC | 1.4M | $120.8M | 2.1% | $117.71 | -27.88% | 12 qtrssince 2019-Q1 | Unchanged 0 |
SPDR S&P BIOTECH ETF | 1.1M | $117.6M | 2.0% | $112.64 | 0.00% | 1 qtr | New 79 |
ARENA PHARMECEUTICALS INC | 1.2M | $114.8M | 2.0% | — | — | 7 qtrssince 2020-Q2 | Decreased 0 |
MONTE ROSA THERAPEUTICS INC | 3.3M | $67.6M | 1.2% | $19.98 | +4.60% | 3 qtrssince 2021-Q2 | Unchanged 0 |
KURA ONCOLOGY INC | 4M | $56M | 1.0% | $28.00 | -49.01% | 7 qtrssince 2020-Q2 | Unchanged 0 |
ACADIA Pharmaceuticals Inc. | 2.2M | $51.3M | 0.9% | $47.53 | -50.48% | 5 qtrssince 2020-Q4 | Unchanged 0 |
SYNDAX PHARMACEUTICALS INC | 2.2M | $47.6M | 0.8% | $20.98 | +3.82% | 5 qtrssince 2020-Q4 | Increased 56 |
Avoro Capital Advisors LLC manages $5.9B across 41 positions as of Q4 2021. Top holdings: HZNP (17.0%), MRTX (12.7%), UTHR (11.2%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 3 new positions, 6 exits, 18 increased. Top move: APLS (INCREASED, conviction 91). Portfolio: $5.9B across 41 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer